Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Genitourinary 1Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1Emergence Delirium 1Delirium 1

Interventions

pembrolizumab 182Magnetic Resonance Spectroscopy 161Specimen Handling 134enzalutamide 125Nivolumab 118Gemcitabine 96Docetaxel 92Radiosurgery 91Prednisone 81Androgen Antagonists 81Abiraterone Acetate 79Radiotherapy 75apalutamide 66Cisplatin 65darolutamide 62Ipilimumab 61Biopsy 61abiraterone 57cabozantinib 55Carboplatin 55Leuprolide 52enfortumab vedotin 50Radiation 47Pluvicto 45Standard of Care 44atezolizumab 41Surveys and Questionnaires 38acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 37X-Rays 37avelumab 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
remimazolam × Genitourinary × 1 year × Clear all
NCT04532606 2025-07-30

Impact of Remimazolam on Prognosis After Bladder Cancer Surgery

Peking University First Hospital

Phase 4 Recruiting
1,128 enrolled
Genitourinary

Emergence Delirium, Urinary Bladder Neoplasms, Delirium

Data powered by HemOnc (CC BY 4.0) Colophon âš¡